Predicting Response to Intense Neoadjuvant Androgen Deprivation Therapy Through Spatial Genomics and Imaging Heterogeneity
Abstract
Objective: Patients enrolled in our clinical study of GnRH agonist plus enzalutamide for six months prior to radical prostatectomy have shown a diversity of responses, including differential responses within the same patient (i.e. one region of tumor responds and another region does not). Based on these initial clinical outcomes, we hypothesize that the specific genomic alterations that arise during tumor development can distinguish exceptional from poor responders to this intense neoadjuvant ADT. We will also test the hypothesis that patients who fail to respond to this intense therapy do so through either pre-existing genomic alterations, adapt to survive with lower levels of androgen receptor activity, or a combination of both. Impact: Further understanding of the genetics of prostate cancer underlying response to treatment is critical to guide patient-specific treatments based on genetic status to improve overall survival. By understanding the genetic factors responsible for either exceptional or failed response to treatment, we will define the biology of lethal prostate cancer to reduce death, while also developing treatments that improve outcomes for men with lethal prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2020
- Accession Number
- AD1145731
Entities
People
- Scott Wilkinson
Organizations
- Geneva Foundation